Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Primary Bioassay of Human Tumor Stem Cells

Anne W. Hamburger, Sydney E. Salmon · Science · 1977 · 1.6K citations

Medicine, Cancer Biology, Oncology +17

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean, Cameron Brennan, Jin‐Yuan Shih et al. · Proceedings of the National Academy of Sciences · 2007 · 1.6K citations

Medicine, Genetics, Oncology +17

Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Luigi Naldini, K. Michael Weidner, Elisa Vigna et al. · The EMBO Journal · 1991 · 667 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Signaling networks assembled by oncogenic EGFR and c-Met

Ailan Guo, Judit Villén, Jon M. Kornhauser et al. · Proceedings of the National Academy of Sciences · 2008 · 505 citations · Full text

Life Sciences, Cancer Biology, Oncology +17